Novartis AG
Novartis AG NVS Peers
See (NVS) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NVS | $112.52 | +0.58% | 222.2B | 17.64 | $6.38 | +3.55% |
| LLY | $722.39 | +0.42% | 684.6B | 58.92 | $12.26 | +0.78% |
| AZN | $70.87 | +0.70% | 439.4B | 28.58 | $2.48 | +2.18% |
| JNJ | $153.57 | +0.75% | 369.5B | 17.06 | $9.00 | +3.28% |
| ABBV | $185.56 | +1.35% | 327.8B | 79.30 | $2.34 | +3.44% |
| NVO | $69.50 | +1.31% | 311.2B | 19.41 | $3.58 | +2.33% |
| MRK | $76.38 | +0.28% | 191.8B | 11.10 | $6.88 | +4.15% |
| AMGN | $283.54 | +1.85% | 152.5B | 25.82 | $10.98 | +3.28% |
| GILD | $111.11 | +2.46% | 138.2B | 14.36 | $7.74 | +2.80% |
| PFE | $23.45 | +1.16% | 133.3B | 16.99 | $1.38 | +7.28% |
Stock Comparison
NVS vs LLY Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 222.2B. In comparison, LLY has a market cap of 684.6B. Regarding current trading prices, NVS is priced at $112.52, while LLY trades at $722.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.64, whereas LLY's P/E ratio is 58.92. In terms of profitability, NVS's ROE is +0.31%, compared to LLY's ROE of +0.77%. Regarding short-term risk, NVS is less volatile compared to LLY. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs AZN Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 222.2B. In comparison, AZN has a market cap of 439.4B. Regarding current trading prices, NVS is priced at $112.52, while AZN trades at $70.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.64, whereas AZN's P/E ratio is 28.58. In terms of profitability, NVS's ROE is +0.31%, compared to AZN's ROE of +0.19%. Regarding short-term risk, NVS and AZN have similar daily volatility (1.18).
NVS vs JNJ Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 222.2B. In comparison, JNJ has a market cap of 369.5B. Regarding current trading prices, NVS is priced at $112.52, while JNJ trades at $153.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.64, whereas JNJ's P/E ratio is 17.06. In terms of profitability, NVS's ROE is +0.31%, compared to JNJ's ROE of +0.30%. Regarding short-term risk, NVS is less volatile compared to JNJ. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs ABBV Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 222.2B. In comparison, ABBV has a market cap of 327.8B. Regarding current trading prices, NVS is priced at $112.52, while ABBV trades at $185.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.64, whereas ABBV's P/E ratio is 79.30. In terms of profitability, NVS's ROE is +0.31%, compared to ABBV's ROE of +0.96%. Regarding short-term risk, NVS is less volatile compared to ABBV. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs NVO Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 222.2B. In comparison, NVO has a market cap of 311.2B. Regarding current trading prices, NVS is priced at $112.52, while NVO trades at $69.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.64, whereas NVO's P/E ratio is 19.41. In terms of profitability, NVS's ROE is +0.31%, compared to NVO's ROE of +0.81%. Regarding short-term risk, NVS is less volatile compared to NVO. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs MRK Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 222.2B. In comparison, MRK has a market cap of 191.8B. Regarding current trading prices, NVS is priced at $112.52, while MRK trades at $76.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.64, whereas MRK's P/E ratio is 11.10. In terms of profitability, NVS's ROE is +0.31%, compared to MRK's ROE of +0.38%. Regarding short-term risk, NVS is less volatile compared to MRK. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs AMGN Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 222.2B. In comparison, AMGN has a market cap of 152.5B. Regarding current trading prices, NVS is priced at $112.52, while AMGN trades at $283.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.64, whereas AMGN's P/E ratio is 25.82. In terms of profitability, NVS's ROE is +0.31%, compared to AMGN's ROE of +0.93%. Regarding short-term risk, NVS is less volatile compared to AMGN. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs GILD Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 222.2B. In comparison, GILD has a market cap of 138.2B. Regarding current trading prices, NVS is priced at $112.52, while GILD trades at $111.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.64, whereas GILD's P/E ratio is 14.36. In terms of profitability, NVS's ROE is +0.31%, compared to GILD's ROE of +0.32%. Regarding short-term risk, NVS is less volatile compared to GILD. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs PFE Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 222.2B. In comparison, PFE has a market cap of 133.3B. Regarding current trading prices, NVS is priced at $112.52, while PFE trades at $23.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.64, whereas PFE's P/E ratio is 16.99. In terms of profitability, NVS's ROE is +0.31%, compared to PFE's ROE of +0.09%. Regarding short-term risk, NVS is less volatile compared to PFE. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs SNY Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 222.2B. In comparison, SNY has a market cap of 129.3B. Regarding current trading prices, NVS is priced at $112.52, while SNY trades at $52.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.64, whereas SNY's P/E ratio is 18.56. In terms of profitability, NVS's ROE is +0.31%, compared to SNY's ROE of +0.08%. Regarding short-term risk, NVS is more volatile compared to SNY. This indicates potentially higher risk in terms of short-term price fluctuations for NVS.
NVS vs CELG-RI Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 222.2B. In comparison, CELG-RI has a market cap of 98.7B. Regarding current trading prices, NVS is priced at $112.52, while CELG-RI trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.64, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, NVS's ROE is +0.31%, compared to CELG-RI's ROE of +0.32%. Regarding short-term risk, NVS is less volatile compared to CELG-RI. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs BMY Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 222.2B. In comparison, BMY has a market cap of 97.4B. Regarding current trading prices, NVS is priced at $112.52, while BMY trades at $47.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.64, whereas BMY's P/E ratio is 17.85. In terms of profitability, NVS's ROE is +0.31%, compared to BMY's ROE of +0.32%. Regarding short-term risk, NVS is less volatile compared to BMY. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs GSK Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 222.2B. In comparison, GSK has a market cap of 81.2B. Regarding current trading prices, NVS is priced at $112.52, while GSK trades at $40.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.64, whereas GSK's P/E ratio is 19.43. In terms of profitability, NVS's ROE is +0.31%, compared to GSK's ROE of +0.22%. Regarding short-term risk, NVS is less volatile compared to GSK. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs HZNP Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 222.2B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, NVS is priced at $112.52, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.64, whereas HZNP's P/E ratio is 61.86. In terms of profitability, NVS's ROE is +0.31%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, NVS is more volatile compared to HZNP. This indicates potentially higher risk in terms of short-term price fluctuations for NVS.
NVS vs BIIB Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 222.2B. In comparison, BIIB has a market cap of 19.5B. Regarding current trading prices, NVS is priced at $112.52, while BIIB trades at $132.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.64, whereas BIIB's P/E ratio is 13.12. In terms of profitability, NVS's ROE is +0.31%, compared to BIIB's ROE of +0.09%. Regarding short-term risk, NVS is less volatile compared to BIIB. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs GRFS Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 222.2B. In comparison, GRFS has a market cap of 6.9B. Regarding current trading prices, NVS is priced at $112.52, while GRFS trades at $8.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.64, whereas GRFS's P/E ratio is 32.15. In terms of profitability, NVS's ROE is +0.31%, compared to GRFS's ROE of +0.03%. Regarding short-term risk, NVS is less volatile compared to GRFS. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs OGN Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 222.2B. In comparison, OGN has a market cap of 2.5B. Regarding current trading prices, NVS is priced at $112.52, while OGN trades at $9.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.64, whereas OGN's P/E ratio is 3.32. In terms of profitability, NVS's ROE is +0.31%, compared to OGN's ROE of +1.82%. Regarding short-term risk, NVS is less volatile compared to OGN. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs CTOR Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 222.2B. In comparison, CTOR has a market cap of 63.8M. Regarding current trading prices, NVS is priced at $112.52, while CTOR trades at $0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.64, whereas CTOR's P/E ratio is -2.35. In terms of profitability, NVS's ROE is +0.31%, compared to CTOR's ROE of -0.15%. Regarding short-term risk, NVS is less volatile compared to CTOR. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs SCLX Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 222.2B. In comparison, SCLX has a market cap of 39.3M. Regarding current trading prices, NVS is priced at $112.52, while SCLX trades at $5.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.64, whereas SCLX's P/E ratio is -0.37. In terms of profitability, NVS's ROE is +0.31%, compared to SCLX's ROE of +0.36%. Regarding short-term risk, NVS is less volatile compared to SCLX. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs SCLXW Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 222.2B. In comparison, SCLXW has a market cap of 30.9M. Regarding current trading prices, NVS is priced at $112.52, while SCLXW trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.64, whereas SCLXW's P/E ratio is N/A. In terms of profitability, NVS's ROE is +0.31%, compared to SCLXW's ROE of +0.36%. Regarding short-term risk, NVS is less volatile compared to SCLXW. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs MIRA Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 222.2B. In comparison, MIRA has a market cap of 22.7M. Regarding current trading prices, NVS is priced at $112.52, while MIRA trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.64, whereas MIRA's P/E ratio is -2.85. In terms of profitability, NVS's ROE is +0.31%, compared to MIRA's ROE of -3.41%. Regarding short-term risk, NVS is less volatile compared to MIRA. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs SRXH Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 222.2B. In comparison, SRXH has a market cap of 6M. Regarding current trading prices, NVS is priced at $112.52, while SRXH trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.64, whereas SRXH's P/E ratio is N/A. In terms of profitability, NVS's ROE is +0.31%, compared to SRXH's ROE of -0.50%. Regarding short-term risk, NVS is less volatile compared to SRXH. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.
NVS vs CRXT Comparison
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 222.2B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, NVS is priced at $112.52, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.64, whereas CRXT's P/E ratio is -0.02. In terms of profitability, NVS's ROE is +0.31%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, NVS is less volatile compared to CRXT. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.